Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, November 20, 2025

Effect of upper-limb robot-assisted therapy combined with pneumatic gloves on upper limb function in young and middle-aged stroke patients: a pilot randomized controlled trial

 No pictures of the gloves so impossible to determine if spastic fingers can get into it. Does no one understand real world problems of stroke survivors and try to fix them? Or is cherry picking subjects the easy and only way to get published? Is publishing more important than survivor recovery?

Effect of upper-limb robot-assisted therapy combined with pneumatic gloves on upper limb function in young and middle-aged stroke patients: a pilot randomized controlled trial


Abstract

Background

This study aimed to evaluate the effects of an end-effector-type upper-limb robot-assisted therapy (UL-RAT) combined with pneumatic gloves (PGs) on improving upper limb function in young and middle-aged stroke patients.

Methods

Forty young and middle-aged stroke patients were recruited and randomized into two groups, including a UL-RAT&PG group and a control group, with 20 cases in each group. The control group received conventional upper limb occupational therapy once a day, 5 days a week, for a total of 4 weeks. The UL-RAT&PG group received the combination of UL-RAT and PGs once a day, 5 days a week, for a total of 4 weeks. To evaluate their upper limb function, the primary assessment indices were the Fugl-Meyer assessment extremities (FMA-UE) and Action Research Arm Test (ARAT), and the secondary assessment indices included the Canadian Occupational Performance Measure (COPM), modified Ashworth Scale (MAS), National Institutes of Health Stroke Scale (NIHSS), and modified Barthel index (MBI). To assess brain plasticity, Quantitative electroencephalogram (qEEG) and diffusion tensor imaging (DTI) were performed. Additionally, Enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay were conducted to evaluate serum brain-derived neurotrophic factor (BDNF) and microRNA-132 (miRNA-132) levels. Finally, the Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and Exercise Adherence Questionnaire Scale (EAQ) were used to assess patients’ emotional states and compliance with the therapy.

Results

After treatment, both groups showed significantly greater improvements in upper limb function. The FMA-UE, ARAT, COPM-executive ability, COPM-satisfaction, and MBI scores of the UL-RAT&PG group were 52.30 ± 1.94, 47.65 ± 7.41, 4.61 ± 1.86, 5.92 ± 1.65, and 87.10 ± 11.11, that all considerably higher than those of the control group (38.6 ± 16.97, 29.90 ± 15.39, 3.39 ± 1.66, 3.61 ± 1.67, and 69.95 ± 17.62), and their NIHSS scores were 1.75 ± 1.12, significantly lower than those of the control group (3.70 ± 1.63). DTABR scores and corticospinal tract (CST) morphology showed positive changes in both groups, indicating an improvement in brain plasticity. The serum BDNF and miRNA-132 levels of both groups were markedly higher than before treatment. In addition, SAS and SDS scores of the control group were 34.55 ± 8.48 and 45.25 ± 12.01, and = UL-RAT&PG groups were 37.85 ± 5.72 and 38.70 ± 8.99, all significantly lower than those before treatment (37.85 ± 9.92 and 49.95 ± 12.59, 42.95 ± 7.62 and 46.10 ± 11.29), indicating that their negative emotions have alleviated. However, the above results of serum BDNF, miRNA-132, SAS, and SDS had no statistical difference between the two groups. Notably, compared to the control group (49.95 ± 12.59), patients in the UL-RAT&PG group had a higher EAQ score (46.10 ± 11.29), indicating better exercise compliance.

Conclusions

The combination of the UL-RAT and PGs can significantly improve(NOT GOOD ENOUGH! Survivors want full recovery!) upper limb function, compliance, serum BDNF, and serum miRNA-132, and attenuate depression and anxiety in young and middle-aged stroke patients.

Trial registration The study was registered on the Chinese Clinical Trial Registry (ChiCTR2500097887).

No comments:

Post a Comment